New response evaluation criteria in solid tumours : Revised RECIST guideline ( version 1 . 1 )

@inproceedings{Eisenhauera2015NewRE,
  title={New response evaluation criteria in solid tumours : Revised RECIST guideline ( version 1 . 1 )},
  author={E. A. Eisenhauera and P. Therasseb and J. Bogaertsc and L. H. Schwartzd and D. Sargente and R. Fordf and J. Danceyg and S. Arbuckh and S. Gwytheri and M. Mooneyg and L. Rubinsteing and L. Shankarg and L. Doddg and R. Kaplanj and D. Lacombec and J. Verweijk},
  year={2015}
}
  • E. A. Eisenhauera, P. Therasseb, +13 authors J. Verweijk
  • Published 2015
Background: Assessment of the change in tumour burden is an important feature of the clinical evaluation of cancer therapeutics: both tumour shrinkage (objective response) and disease progression are useful endpoints in clinical trials. Since RECIST was published in 2000, many investigators, cooperative groups, industry and government authorities have adopted these criteria in the assessment of treatment outcomes. However, a number of questions and issues have arisen which have led to the… CONTINUE READING